Dianthus Therapeutics (DNTH) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Dianthus Therapeutics (DNTH) is Neutral.

The composite score behind that read is -0.13, weighing +0.28 of bullish evidence against -0.34 bearish.

Dianthus Therapeutics last closed at $84.88, -0.61% on the session.

Against the IVW growth benchmark the position is -0.45% over the forecast window.

The read is built from 11 underlying insights — 3 bullish and 8 bearish.

Agreement across those insights is 73%.

1 graded prediction for DNTH so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Dianthus Therapeutics in the 26th percentile on return on equity, where 100 is best.

Dianthus Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $4.78B.

StockMap tracks Dianthus Therapeutics as the 55th largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Dianthus Therapeutics ranks 97th of 377 in the group, against a group median of -0.21.